Compare Cardinal Health Inc (CAH) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs iShares MSCI China ETF — how do they compare? Cardinal Health Inc trades at $234.53 (market cap $55.88B), while iShares MSCI China ETF trades at $55.08. The key difference: Cardinal Health Inc pays a 0.86% dividend while iShares MSCI China ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| CAH | MCHI | |
|---|---|---|
Market Cap | $55.88B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.26 | $66.99 |
52-Week Low | $146.04 | $50.48 |
Enterprise Value | $59.91B | — |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
MCHI trades at $55.01, down 3.37% amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, with exports jumping 23% in July (CNBC, 2026-08-06). Recent institutional activity includes Empowered Funds acquiring $1.47M in shares (Defense World, 2026-08-08).
MCHI presents value opportunity trading at significant discount to US indices, with financial sector benefiting from China's yield curve. Key risks include US-China trade tensions and regulatory uncertainty. The $295B AI infrastructure plan (Bloomberg, 2026-06-09) provides long-term growth catalyst, though near-term volatility persists amid geopolitical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
